CHAMPSI FARAH 3, filed Sep 20, 2005: FORM 3 SUBMISSION
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 09/20/2005 |
3. Issuer Name and Ticker or Trading Symbol
INTARCIA THERAPEUTICS, INC [ ITCA ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Series B Preferred Stock | (1) | (2) | Common Stock | 388,888(3)(4)(5) | (3) | I | See Footnotes(4)(6)(7)(8) |
| Series C Preferred Stock | (1) | (2) | Common Stock | 130,207(4)(5)(9) | (9) | I | See Footnotes(4)(6)(7)(8) |
| Series D Preferred Stock | (1) | (2) | Common Stock | 1,909,721(4)(5)(10) | (10) | I | See Footnotes(4)(5)(6)(7)(8) |
| Series E Preferred Stock | (1) | (2) | Common Stock | 1,470,586(4)(5)(10) | (10) | I | See Footnotes(4)(5)(6)(7)(8) |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
| Explanation of Responses: |
| 1. Immediately |
| 2. N/A |
| 3. The Series B Preferred Stock is convertible into Common Stock on a 1:0.25 basis. |
| 4. Alta Partners ("AP") provides investment advisory services to several venture capital funds including, Alta California Partners II, L.P. ("ACPII"), Alta Embarcadero Partners II, LLC ("AEPII") & Alta California Partners II, L.P.-New Pool ("ACPIINP"). ACPII beneficially owns 1,541,305 shares ("sh") of Series B Preferred Stock ("Ser B"), 314,098 sh Series C Preferred Stock ("Ser C"), 2,057,341 sh Series D Preferred Stock ("Ser D") & 1,936,322 sh Series E Preferred Stock ("Ser E"). AEPII beneficially owns 14,251 sh Ser B, 3,968 sh Ser C, 25,992 sh Ser D & 24,463 sh Ser E. ACPIINP beneficially owns 5,882,353 sh Ser E. The respective general partners, members & managing directors of ACPII, AEPII & ACPIINP exercise sole voting & investment power with respect to the shares owned by such funds. |
| 5. Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds including, Alta BioPharma Partners II, L.P. ("ABPII") & Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). ABPII beneficially owns 20,094,126 shares ("sh") of Series D Preferred Stock ("Ser D") & 9,456,059 sh of Series E Preferred Stock ("Ser E"). AEPII beneficially owns 739,208 sh Ser D & 347,863 sh of Ser E. The respective general partners, managing directors & managers of ABPII & AEBPII exercise sole voting & investment power with respect to the shares owned by such funds. |
| 6. Jean Deleage, Guy Nohra, Garrett Gruener, Daniel Janney & Alix Marduel (collectively known as the "principals") of Alta Partners ("AP") are members of Alta California Management Partners II, LLC & Alta California Management Partners II- New Pool, LLC (which are the general partners of Alta California Partners II, L.P. & Alta California Partners II, L.P.-New Pool respectively), & members of Alta Embarcadero Partners II, LLC. As members of such funds, they may be deemed to share voting & investment powers for the shares held by the funds. The principals of AP disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein. |
| 7. Jean Deleage, Director, is a member of Alta California Management Partners II, LLC (which is the general partner of Alta California Partners II, L.P. & Alta California Partners II, L.P.- New Pool), a member of Alta Embarcadero Partners II, LLC, a managing director of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.), and a manager of Alta Embarcadero BioPharma Partners II, LLC. As a member, managing director and manager he may be deemed to share voting and investment powers for the shares held by the funds. He disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein. |
| 8. Jean Deleage, Alix Marduel and Farah Champsi (collectively known as the "principals") of Alta Partners II, Inc. ("APII") are managing directors of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.) and managers of Alta Embarcadero BioPharma Partners II, LLC. As managing directors & managers of such funds, they may be deemed to share voting & investment powers for the shares held by the foregoing funds. The principals of APII disclaim benefical ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein. |
| 9. The Series C Preferred Stock is convertible into Common Stock on a 1:0.409375 basis. |
| 10. The Series D Preferred Stock and the Series E Preferred Stock are convertible into Common Stock on a 1:0.0833333 basis. |
| Remarks: |
| Cross-reference with Form 3 filed on behalf of Jean Deleage dated 9/20/2005. |
| Jean Deleage, President | 09/20/2005 | |
| Farah Champsi, Managing Director | 09/20/2005 | |
| Farah Champsi, Manager | 09/20/2005 | |
| Farah Champsi | 09/20/2005 | |
| Alix Marduel, Member | 09/20/2005 | |
| Farah Champsi, Managing Director | 09/20/2005 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||